NEW YORK (TheStreet) -- RATINGS CHANGES Celgene was initiated with a buy rating at Canaccord Genuity. Twelve-month price target is $156. Revlimid should drive growth in the next several quarters, Canaccord Genuity said. Centurylink was downgraded at Goldman Sachs to sell from neutral. Twelve-month price target is $33. Margins and free cash flow will likely deteriorate in the coming quarters, Goldman Sachs said. Express was upgraded at Piper Jaffray to overweight from neutral. Twelve-month price target is $16. Promotional activity is lower, which should boost margins, Piper Jaffray said. Legg Mason was upgraded at Jefferies to buy from hold. Twelve-month price target is $67. Company is still attracting assets and can deliver consistent growth, Jefferies said. Insulet was downgraded at Canaccord Genuity to hold from buy. Twelve-month price target is $35. Estimates were also cut, given new patient numbers and growth trends, Canaccord Genuity said. Rackspace was upgraded at Pacific Crest to outperform. Company is realizing higher margins and is attractively valued, Pacific Crest said. Twelve-month price target is $58. Waddell & Reed was downgraded at Jefferies to hold from buy. Valuation call, based on a 12-month price target of $50, Jefferies said. Williams-Sonoma was downgraded at Piper Jaffray to neutral from overweight. Twelve-month price target is $84. Expect higher promotional activity in the industry, Piper Jaffray said. Must Read: 16 Rock-Solid Dividend Stocks With 50 Years of Increasing Dividends and Market-Beating Performance Editor's note: To see analysts' stock comments and changes to price targets and earnings estimates, go to "Street Notes," which is available only to Real Money subscribers. To find out how to become a subscriber, please click here. Follow TheStreet on Twitter and become a fan on Facebook.
Click to view a price quote on CELG. Click to research the Drugs industry.
from Latest TSC Headlines http://ift.tt/17pXHxM
No comments:
Post a Comment